Acrivon Therapeutics
ACRV
ACRV
41 hedge funds and large institutions have $74.6M invested in Acrivon Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
48% less capital invested
Capital invested by funds: $144M → $74.6M (-$69.7M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Holders
41
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$268K | |
| 2 | +$228K | |
| 3 | +$227K | |
| 4 |
BlackRock
New York
|
+$182K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$157K |
Top Sellers
| 1 | -$72.9K | |
| 2 | -$56.9K | |
| 3 | -$15K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.93K |
| 5 |
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
|
-$2.4K |